The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...

The primary exposure was the use of GLP-1 agonists, including exenatide, liraglutide, dulaglutide, and semaglutide (with ...

However, the overall safety profile of taspoglutide was clearly worse than exenatide with respect to gastrointestinal tolerability, systemic allergic reactions, and injection-site reactions.

These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Sorry, we have no data ...

Depending on the medication, the effects can last for a minimum of 24 hours to a few weeks. Examples include dulaglutide, ...

Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. Exenatide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ...